Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

OPINIONS

 bernstein-downgrades-plains-all-american-to-market-perform-lowers-price-target-to-145

Bernstein analyst Jean Ann downgrades Plains All American (NASDAQ:PAA) from Outperform to Market Perform and lowers the pric...

 credit-suisse-maintains-outperform-on-cme-group-raises-price-target-to-198

Credit Suisse analyst Gautam Sawant maintains CME Group (NASDAQ:CME) with a Outperform and raises the price target from $192...

 medicenna-therapeutics-q3-eps-0015-beats-007-estimate-cash-equivalents-of-362m

Medicenna Therapeutics (NASDAQ:MDNA) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate o...

 catalent-reiterates-fy23-guidance-with-revenue-of-4625b-4875b-compared-to-consensus-of-508b-and-adjusted-ebitda-of-122b-13b

The company expects FY23 adjusted income of $567 million - $648 million.

 ac-immune-awarded-new-grants-from-mjff-target-als-supporting-programs-targeting-tdp-43

The Michael J. Fox Foundation grant supports the development of AC Immune's first-in-class TDP-43 PET tracer program ...

 ares-capital-q4-eps-063-beats-056-estimate

Ares Capital (NASDAQ:ARCC) reported quarterly earnings of $0.63 per share which beat the analyst consensus estimate of $0.56 by...

 incyte-q4-adjusted-eps-062-beats-058-estimate-sales-92670m-beat-88110m-estimate

Incyte (NASDAQ:INCY) reported quarterly earnings of $0.62 per share which beat the analyst consensus estimate of $0.58 by 6.9 p...

 fiserv-q4-adj-eps-191-beats-190-estimate-adj-sales-436b-beat-434b-estimate

Fiserv (NASDAQ:FISV) reported quarterly earnings of $1.91 per share which beat the analyst consensus estimate of $1.90 by 0.53 ...

 barclays-maintains-overweight-on-post-hldgs-raises-price-target-to-105

Barclays analyst Andrew Lazar maintains Post Hldgs (NYSE:POST) with a Overweight and raises the price target from $102 to $105.

 insiders-buying-ameriserv-financial-and-2-other-penny-stocks

The Dow Jones dropped by over 100 points on Friday. When insiders purchase or sell shares, it indicates their confidence or con...

 akoustis-technologies-q2-adj-eps-019-beats-025-estimate-sales-587m-miss-592m-estimate

Akoustis Technologies (NASDAQ:AKTS) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of...